Literature DB >> 1613819

Collagen IV is present in the developing CNS during Drosophila neurogenesis.

C Mirre1, Y Le Parco, B Knibiehler.   

Abstract

By means of immunocytochemistry with a battery of specific antibodies, we describe the expression of the collagen IV chain produced by the gene DCg1 during the two phases of Drosophila neurogenesis. DgC1 was not expressed in neuronal tissues as shown by in situ hybridization, but the onset of its expression in cells of mesodermal origin was concomitant with the appearance of collagen IV on early axon pathways and peripheral nerve roots in the embryonic developing CNS. A similar situation was found during imaginal CNS development at metamorphosis, when collagen IV immunoreactivity was detected on centrifugal and centripetal nerve pathways, and specially on retinula axons that develop from the eye imaginal disc towards the lamina anlage in the brain optic lobe. Our results strongly suggest that collagen IV could be involved, together with other informative molecules of basement membranes, in a dynamic process of cell-matrix interactions during the establishment of initial axon pathways and neurite outgrowth in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1613819     DOI: 10.1002/jnr.490310120

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  3 in total

Review 1.  Extracellular matrix and its receptors in Drosophila neural development.

Authors:  Kendal Broadie; Stefan Baumgartner; Andreas Prokop
Journal:  Dev Neurobiol       Date:  2011-11       Impact factor: 3.964

2.  The function of type IV collagen during Drosophila embryogenesis.

Authors:  C Borchiellini; J Coulon; Y Le Parco
Journal:  Rouxs Arch Dev Biol       Date:  1996-05

3.  Recombinant human bone morphogenetic protein 2B stimulates PC12 cell differentiation: potentiation and binding to type IV collagen.

Authors:  V M Paralkar; B S Weeks; Y M Yu; H K Kleinman; A H Reddi
Journal:  J Cell Biol       Date:  1992-12       Impact factor: 10.539

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.